



Case 3:04/1

TECH CENTER 1600/2900

APR 04 2003

RECEIVED

7/1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Joel Krasnow

SERIAL NO.: 10/067,128

FILED: 4 FEBRUARY 2002

GROUP ART UNIT:

EXAMINER:

DATE: March 24, 2003

TITLE: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR & SEX STEROIDS AS A COMBINATIONS THERAPY FOR THE TREATMENT & PREVENTION OF DYSMENORRHEA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

James M. Warner

James M. Warner
Attorney for Applicants
Registration No. 45,199
(314) 274-3642 (St. Louis)

Pharmacia Corporation
P.O. Box 1027
Chesterfield, MO 63006

RECEIVED

APR 04 2003

TECH CENTER 1600/2900
Sheet 1 of 1FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICESUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET
NO.: 3414/1APPLICATION NO.:
10/067,128

INVENTOR: Joel Krasnow

Filed: 02/04/2002

Group:

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO 97/31631	09/04/1997	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)